J&J’s new launches deliver, but overall sales fall short on hep C, strong dollar

Carly Helfand

Johnson & Johnson's hep C have been nosediving, and the fourth quarter provided more of the same on that front. But in the quarter, a took a toll on the company's top line, too, dragging below analyst estimates.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS